Lamivudine Therapy of Hepatitis B in Japan

  • Michio Sata
Conference paper


HBV carrier rate is now 0.67% in Japanese population. The most prevalent HBV genotype is genotype C (85%) in patients with chronic HBV carriers in Japan. Hepatitis activity is more severe and response to anti-viral therapy is poor in genotype C compared with genotype B. There are questions whether we should use lamivudine for long-term.


Chronic Hepatitis Adefovir Dipivoxil Lamivudine Therapy Lamivudine Treatment Virologic Breakthrough 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudineuntreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584–586.PubMedCrossRefGoogle Scholar
  2. 2.
    Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145–1153.PubMedCrossRefGoogle Scholar
  3. 3.
    Ide T, Kumashiro R, Suzuki H, Tanikawa K, Sata M. Two-year follow-up study after treatment with lamivudine for chronic hepatitis B: seven cases reported. Hepatol Res 2000;17:197–204.PubMedCrossRefGoogle Scholar
  4. 4.
    Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Thl response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000;32:604–609.PubMedCrossRefGoogle Scholar
  5. 5.
    Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573–577.PubMedCrossRefGoogle Scholar
  6. 6.
    Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, Francavilla A. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805–810.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34:583–589.PubMedCrossRefGoogle Scholar
  8. 8.
    Ide T, Kumashiro R, Sata M, et al. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol 2003;98:2048–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 2001;21:76–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207–210.PubMedCrossRefGoogle Scholar
  11. 11.
    Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308–312.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Michio Sata
    • 1
  1. 1.Second Department of MedicineKurume University School of MedicineFukuokaJapan

Personalised recommendations